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In Response:
We appreciate your interest in 
our article published in the Journal of 
Thoracic Oncology1 and thank you for 
the opportunity to answer your questions.
In our article, we analyzed the 
influence of diabetes mellitus on the 
survival of patients with lung cancer. 
We found that lung cancer patients with 
diabetes mellitus had a longer survival 
compared with patients without diabe-
tes mellitus. The mean age at baseline 
in the Nord-Trøndelag Health Study 
(HUNT) for patients with lung cancer 
was 59 years, and 4.5% among these 
had self-reported diabetes mellitus. 
Similar prevalence has been reported 
in other studies for comparable age 
groups,2 and these estimates are also 
in line with the prevalence in the total 
HUNT study population at this age.3,4 
The mean age at the time of diagnoses 
of lung cancer was 70 years.
In the HUNT study, diabetes mel-
litus was defined by the answer “yes” to 
the question “Do you have or have you 
had diabetes?” independent of whether or 
not the person used medication for diabe-
tes mellitus. Self-reported diabetes mel-
litus is a widely accepted and used tool 
in epidemiological studies.5 The question 
on self-reported diagnosis has also been 
validated in the HUNT study popula-
tion.6 We therefore believe that our defi-
nition of the variable “diabetes mellitus” 
can be used in the current setting.
Dr. Satoh is of course right regard-
ing change in the treatment of diabetes 
mellitus in the last decades. We agree 
that information on whether patients 
Journal of Thoracic Oncology
7
9
Copyright © 2012 by the International Association for the Study of Lung Cancer
1556-0864
JTO
202173
Letters to the Editor
Letters to the Editor
2012
September
00
00
10.1097/JTO.0b013e3182614877
Anjana
Letters to the Editor
Prolonged Survival in 
Lung Cancer Patients 
with Diabetes Mellitus
Disclosure: The author declares no conflict of 
interest.
Address for correspondence: Peter Hatlen, MD, 
Department of Circulation and Medical Imaging, 
Faculty of Medicine, Norwegian University of 
Science and Technology, Pb.: 8905 MTFS, 7491 
Trondheim, Norway. E-mail: Peter.Hatlen@ntnu.no
Copyright © 2012 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/12/0709-e17
had diabetes mellitus or not, closer to 
or at the time of diagnosis would have 
improved our study and reduced mis-
classification. This would, however, 
reduce nondifferential misclassifica-
tion, and this should rather strengthen 
than weaken the report on associations.
All participants in the HUNT study 
are identified with an eleven-digit national 
identification number that all Norwegians 
are given at birth or immigration. All 
data regarding HUNT participants are 
linked by this key, and no duplicate data 
set are present in the HUNT database.
Diabetes mellitus was no exclusion 
criteria in the pemetrexed-gemcitabine 
study or in the Norwegian Lung Cancer 
Biobank (Norwegian Lung Cancer 
Biobank study, and the prevalence of 
diabetes mellitus was 3.9% (mean age 
64 years) and 8.1% (mean age 68 years), 
respectively. Therefore, we have no indi-
cation of diabetes mellitus being the 
cause of any selection bias in the PEG 
or NLCB study. In these studies, we used 
the medical journal to identify whether 
patients had diabetes mellitus or not.
Peter Hatlen, MD
Norwegian University of Science and 
Technology
Trondheim 
Norway
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To the Editor:
We read with interest the recent 
article by Hatlen et al. (November 
2011)1 regarding survival in lung can-
cer patients with diabetes mellitus. As 
can be seen from the title of our article2 
in the Reference section of Hatlen et 
al.’s article, we have a strong interest 
in this issue. We can understand the 
results of this study, but we cannot 
accept the hypothesis that lung cancer 
patients with diabetes mellitus have 
an increased survival rate compared 
with those without. Although the study 
reported by Hatlen et al. in the article 
had a large sample size, only 84 of 
1852 patients (4.5%) had diabetes mel-
litus; so this ratio was apparently lower 
than the prevalence of diabetes mellitus 
in developed countries.3 In their study, 
patients with diabetes mellitus were 
defined as those who answered that 
they had diabetes mellitus and those 
who used medication for the same. We 
would like to know from the authors 
about whether that was appropriate. 
Two -thirds of their patients were par-
ticipants in the Nord-Trøndelag Health 
Study (HUNT), a population-based 
prospective cohort study started in 
1984. However, median survivals of the 
patients with diabetes mellitus in the 
HUNT study were very short (8 and 6 
months); this contrasts with the median 
survivals in the present-day situation, 
as treatments for diabetes mellitus have 
progressed a lot during the last two 
decades. Therefore, we wonder whether 
the study included old data. Because 
the periods of the Nord-Trøndelag 
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